These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 34011260)

  • 1. Inebilizumab-cdon: USFDA Approved for the Treatment of NMOSD (Neuromyelitis Optica Spectrum Disorder).
    Ali F; Sharma K; Anjum V; Ali A
    Curr Drug Discov Technol; 2022; 19(1):e140122193419. PubMed ID: 34011260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inebilizumab: First Approval.
    Frampton JE
    Drugs; 2020 Aug; 80(12):1259-1264. PubMed ID: 32729016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Nie T; Blair HA
    CNS Drugs; 2022 Oct; 36(10):1133-1141. PubMed ID: 36070074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and Safety of Inebilizumab, an Anti-CD19 Monoclonal Antibody, for the Treatment of Neuromyelitis Optica Spectrum Disorder: Based on the N-MOmentum Trial].
    Fujihara K; Sato H
    Brain Nerve; 2024 Oct; 76(10):1153-1160. PubMed ID: 39370840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inebilizumab for treatment of neuromyelitis optica spectrum disorder.
    J Tullman M; Zabeti A; Vuocolo S; Dinh Q
    Neurodegener Dis Manag; 2021 Oct; 11(5):341-352. PubMed ID: 34486379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
    Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
    Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
    Cree BAC; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; Lublin FD; Drappa J; Barron G; Madani S; Ratchford JN; She D; Cimbora D; Katz E;
    Lancet; 2019 Oct; 394(10206):1352-1363. PubMed ID: 31495497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inebilizumab in AQP4-Ab-positive neuromyelitis optica spectrum disorder.
    Siebert N; Duchow A; Paul F; Infante-Duarte C; Bellmann-Strobl J
    Drugs Today (Barc); 2021 May; 57(5):321-336. PubMed ID: 34061127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of inebilizumab in Asian participants with neuromyelitis optica spectrum disorder: Subgroup analyses of the N-MOmentum study.
    Fujihara K; Kim HJ; Saida T; Misu T; Nagano Y; Totsuka N; Iizuka M; Kido S; Terata R; Okumura K; Hirota S; Cree BAC
    Mult Scler Relat Disord; 2023 Nov; 79():104938. PubMed ID: 37769428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.
    Bennett JL; Aktas O; Rees WA; Smith MA; Gunsior M; Yan L; She D; Cimbora D; Pittock SJ; Weinshenker BG; Paul F; Marignier R; Wingerchuk D; Cutter G; Green A; Hartung HP; Kim HJ; Fujihara K; Levy M; Katz E; Cree BAC;
    EBioMedicine; 2022 Dec; 86():104321. PubMed ID: 36370634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
    Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk D; Fujihara K; Paul F; Cutter GR; Green AJ; Aktas O; Hartung HP; Lublin FD; Williams IM; Drappa J; She D; Cimbora D; Rees W; Smith M; Ratchford JN; Katz E; Cree BAC;
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33771837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism.
    Kim HJ; Aktas O; Patterson KR; Korff S; Kunchok A; Bennett JL; Weinshenker BG; Paul F; Hartung HP; Cimbora D; Smith MA; Mittereder N; Rees WA; She D; Cree BAC
    Ann Clin Transl Neurol; 2023 Dec; 10(12):2413-2420. PubMed ID: 37804003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inebilizumab for treatment of neuromyelitis optica spectrum disorder in patients with prior rituximab use from the N-MOmentum Study.
    Flanagan EP; Levy M; Katz E; Cimbora D; Drappa J; Mealy MA; She D; Cree BAC
    Mult Scler Relat Disord; 2022 Jan; 57():103352. PubMed ID: 35158461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic Modeling of Inebilizumab in Subjects with Neuromyelitis Optica Spectrum Disorders, Systemic Sclerosis, or Relapsing Multiple Sclerosis.
    Yan L; Kimko H; Wang B; Cimbora D; Katz E; Rees WA
    Clin Pharmacokinet; 2022 Mar; 61(3):387-400. PubMed ID: 34718986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD.
    Cree BA; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk D; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; Williams IM; Drappa J; She D; Cimbora D; Rees W; Ratchford JN; Katz E
    Mult Scler; 2021 Nov; 27(13):2052-2061. PubMed ID: 33538237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder.
    Marignier R; Pittock SJ; Paul F; Kim HJ; Bennett JL; Weinshenker BG; Wingerchuk DM; Green AJ; Fujihara K; Cutter G; Aktas O; Hartung HP; Drappa J; Ratchford JN; She D; Smith M; Rees W; Cimbora D; Katz E; Cree BAC;
    Mult Scler Relat Disord; 2022 Jan; 57():103356. PubMed ID: 35158465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
    Duchow A; Paul F; Bellmann-Strobl J
    Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic modelling and exposure-response assessment of inebilizumab in subjects with neuromyelitis optica spectrum disorders.
    Yan L; Wang B; She D; Mitchell B; Criste R; Cimbora D; Katz E; Rees WA
    Br J Clin Pharmacol; 2022 Aug; 88(8):3803-3812. PubMed ID: 35332558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inebilizumab-cdon.
    Am J Health Syst Pharm; 2020 Oct; 77(22):1812-1814. PubMed ID: 32936251
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
    Rensel M; Zabeti A; Mealy MA; Cimbora D; She D; Drappa J; Katz E
    Mult Scler; 2022 May; 28(6):925-932. PubMed ID: 34595983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.